We are excited to announce that Eagle IP will be returning as a sponsor and exhibitor at the upcoming Life Sciences Patent Network (LSPN) North America Spring conference in Boston. Our President and Managing Director, Ms. Jennifer Che, is one of the distinguished speakers at the event. Organized by Life Sciences Intellectual Property Review, this event will take place on May 6-7, 2025, at the Hyatt Regency Boston located at One Avenue de Lafayette, Boston, MA 02111.

Come join us there and meet us at our booth!

Every year, LSPN brings together experts from pharmaceutical, biotech, and medtech industries to discuss innovation and IP protections. The conference covers patentability, eligibility, prosecution, and litigation, offering insights for the entire patent protection lifecycle in the US.

For more information about the conference and to complete your registration, please visit: https://www.lspnnorthamerica.com

If you won’t be able to attend LSPN but will be in Boston and would like to schedule a meeting, please let us know. We would be happy to arrange a convenient time to connect.

We are looking forward to seeing you in Boston!

Our Past Events

Recommended Insights

How Smart is a "Skilled Person in the Art"?

11 April 2022
Let’s start with a riddle: can you name a person who has read every book, every journal, conducted every known experiment, and is knowledgeable about every single patent prosecution / litigation in the world? The answer? A “skilled person in the art.” This person is also known as a “person having ordinary skill in the […]

How will Civil Cases Work under the Patent Linkage Provision in the New Chinese Patent Law?

20 November 2020
The Supreme People’s Court has just issued draft regulations for comment regarding how new Article 76 will work in conjunction with civil procedure law. The period to submit comments ends December 14, 2020, and the final version will come into force June 1, 2021, together with the new Chinese Patent Law. The Backdrop: New Chinese […]

No % homology? How to craft allowable claim scope around sequences to comply with China’s strict written description requirements

23 November 2018
Since 2010, the Patent Re-examination Board (PRB) has published the top 10 patent invalidation cases of the year in April of each year. The selection criteria are high social concern, significant impact on the related industry, or involve difficult legal issues and important examination criteria. Below is one of the top 10 cases that discusses […]
Tapentadol.svg

Polymorph Patents in China: What is the Standard for Inventiveness for New Crystal Forms?

14 July 2020
This case is focused on polymorphs, namely what are the standards for novelty and inventiveness when it comes to new crystal forms of a known drug? A recent Supreme People’s Court decision in China is illustrative of the way Chinese courts are thinking about polymorph patents in China. Grünenthal is a German pharmaceutical company and […]
Top crossarrow-right